Sister Study Cohort Status: Data Release 11

| | Vital Status | | | | | | | |
|--|--------------------|------|----------------------------|------|-----------------------|------|--------|------|
| | Alive ¹ | | Incapacitated ² | | Deceased ² | | Total | |
| Follow-up status | N | % | N | % | N | % | N | % |
| Overall | | | | | | | | |
| Refused study participation ³ | 2,537 | | 0 | | 190 | | 2,727 | |
| Completed most recent follow-up ⁴ | 38,708 | 86.8 | 22 | 5.8 | 16 | 0.5 | 38,746 | 80.5 |
| Did not complete most recent follow-up | 5,893 | 13.2 | 357 | 94.2 | 3,161 | 99.5 | 9,411 | 19.5 |
| TOTAL | 47,138 | | 379 | | 3,367 | | 50,884 | |
| Breast cancer cases ⁵ | | | | | | | | |
| Refused study participation ³ | 224 | -1 | 0 | | 33 | | 257 | |
| Completed most recent follow-up ⁴ | 3,394 | 85.2 | 4 | 11.8 | 5 | 1.4 | 3,403 | 77.9 |
| Did not complete most recent follow-up | 591 | 14.8 | 30 | 88.2 | 347 | 98.6 | 968 | 22.1 |
| TOTAL | 4,209 | | 34 | | 385 | | 4,628 | |

¹ Excludes incapacitated participants

² Questionnaire response was completed by proxy. Deceased as of Data Release 11; mortality cutoff was 12/31/2020

³ Refused overall study participation prior to or during most recent follow-up and prior to 9/30/2021 (Data Release 11 follow-up cutoff). Includes 5 participants who withdrew their data; the remainder refused future participation in data collection

⁴ Completed either an annual or detailed follow-up during 2020-21 field period

 $^{^{5}}$ Breast cancer cases are those with an incident diagnosis of invasive breast cancer or DCIS in Data Release 11